NCT01495169View on ClinicalTrials.gov

Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Safety and Tolerability of Iloperidone
Interventions
DRUG

iloperidone (oral tablet)

iloperidone 12 to 24 mg/day followed by 26 weeks of flexible dosing (6 to 24 mg/day)

Trial Locations (10)

21205

Novartis Investigative Site, Baltimore

30308

Novartis Investigative Site, Atlanta

33161

Novartis Investigative Site, North Miami

45219

Novartis Investigative Site, Cincinnati

63044

Novartis Investigative Site, St Louis

83814

Novartis Investigative Site, Coeur d'Alene

84106

Novartis Investigative Site, Salt Lake City

92626

Novartis Investigative Site, Costa Mesa

08053

Novartis Investigative Site, Marlton

44106-5000

Novartis Investigative Site, Cleveland

Sponsors
All Listed Sponsors
lead

Vanda Pharmaceuticals

INDUSTRY